

MERIDIAN BIOSCIENCE INC  
Form 10-Q  
August 09, 2016  
Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**x QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended June 30, 2016**

**OR**

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-14902**

**MERIDIAN BIOSCIENCE, INC.**

**Incorporated under the laws of Ohio**

**31-0888197**

**(I.R.S. Employer Identification No.)**

**3471 River Hills Drive**

**Cincinnati, Ohio 45244**

**(513) 271-3700**

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| <b>Class</b>               | <b>Outstanding July 31, 2016</b> |
|----------------------------|----------------------------------|
| Common Stock, no par value | 42,086,737                       |

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****TABLE OF CONTENTS TO QUARTERLY REPORT ON FORM 10-Q**

|   | <b>Page(s)</b> |
|---|----------------|
| <b>PART I. <u>FINANCIAL INFORMATION</u></b>   |                |
| Item 1. Financial Statements (Unaudited)  |                |
| <u>Condensed Consolidated Statements of Operations Three and Nine Months Ended June 30, 2016 and 2015</u>           | 1              |
| <u>Condensed Consolidated Statements of Comprehensive Income Three and Nine Months Ended June 30, 2016 and 2015</u> | 2              |
| <u>Condensed Consolidated Statements of Cash Flows Nine Months Ended June 30, 2016 and 2015</u>                     | 3              |
| <u>Condensed Consolidated Balance Sheets June 30, 2016 and September 30, 2015</u>                                   | 4-5            |
| <u>Condensed Consolidated Statement of Changes in Shareholders' Equity Nine Months Ended June 30, 2016</u>          | 6              |
| <u>Notes to Condensed Consolidated Financial Statements</u>   | 7-13           |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                | 14-21          |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>   | 21             |
| Item 4. <u>Controls and Procedures</u>  | 21             |
| <b>PART II. <u>OTHER INFORMATION</u></b>  |                |
| Item 1A. <u>Risk Factors</u>  | 22             |
| Item 5. <u>Other Information</u>  | 22             |
| Item 6. <u>Exhibits</u>   | 22             |
| <u>Signature</u>  | 23             |
| <b><u>FORWARD-LOOKING STATEMENTS</u></b>  |                |

*This Quarterly Report on Form 10-Q contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as estimates, anticipates, projects, plans, seeks, may, will, expects, intends, believes, should and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. Specifically, Meridian's forward-looking statements are, and will be, based on management's then-current views*

*and assumptions regarding future events and operating performance. Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition, and its ability to effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company's ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessional pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian's operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian's growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian's operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian's ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. Efforts to reduce the U.S. federal deficit, breaches of Meridian's information technology systems and natural disasters and other events could have a materially adverse effect on Meridian's results of operations and revenues. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.*

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Operations (Unaudited)****(in thousands, except per share data)**

|   | <b>Three Months Ended<br/>June 30,</b> |             | <b>Nine Months Ended<br/>June 30,</b> |             |
|---|--|-------------|---------------------------------------|-------------|
|   | <b>2016</b>                            | <b>2015</b> | <b>2016</b>                           | <b>2015</b> |
| NET REVENUES  | \$ 50,665                              | \$ 48,204   | \$ 149,084                            | \$ 147,762  |
| COST OF SALES   | 17,756                                 | 17,873      | 51,020                                | 55,673      |
| GROSS PROFIT  | 32,909                                 | 30,331      | 98,064                                | 92,089      |
| OPERATING EXPENSES  |  |             |                                       |             |
| Research and development  | 3,546                                  | 3,214       | 10,056                                | 9,685       |
| Selling and marketing   | 8,085                                  | 6,184       | 21,738                                | 18,745      |
| General and administrative  | 7,537                                  | 6,535       | 22,306                                | 20,860      |
| Acquisition-related costs   |  |             | 1,481                                 |             |
| Total operating expenses  | 19,168                                 | 15,933      | 55,581                                | 49,290      |
| OPERATING INCOME  | 13,741                                 | 14,398      | 42,483                                | 42,799      |
| OTHER INCOME (EXPENSE)  |  |             |                                       |             |
| Interest income   | 22                                     | 6           | 42                                    | 18          |
| Interest expense  | (427)                                  |             | (470)                                 |             |
| Other, net  | 65                                     | (99)        | (163)                                 | (892)       |
| Total other income (expense)  | (340)                                  | (93)        | (591)                                 | (874)       |
| EARNINGS BEFORE INCOME TAXES  | 13,401                                 | 14,305      | 41,892                                | 41,925      |
| INCOME TAX PROVISION  | 4,647                                  | 5,203       | 15,154                                | 14,852      |
| NET EARNINGS  | \$ 8,754                               | \$ 9,102    | \$ 26,738                             | \$ 27,073   |
| BASIC EARNINGS PER COMMON SHARE                                     | \$ 0.21                                | \$ 0.22     | \$ 0.64                               | \$ 0.65     |
| DILUTED EARNINGS PER COMMON SHARE                                   | \$ 0.21                                | \$ 0.22     | \$ 0.63                               | \$ 0.64     |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES<br>OUTSTANDING - BASIC     | 42,076                                 | 41,714      | 42,000                                | 41,647      |
| EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED<br>SHARES AND UNITS | 387                                    | 379         | 379                                   | 352         |

|   |        |        |        |        |
|---|--------|--------|--------|--------|
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES<br>OUTSTANDING - DILUTED | 42,463 | 42,093 | 42,379 | 41,999 |
|---|--------|--------|--------|--------|

ANTI-DILUTIVE SECURITIES:

|  |     |     |     |     |
|--|-----|-----|-----|-----|
| Common share options and restricted shares and units | 465 | 493 | 449 | 567 |
|--|-----|-----|-----|-----|

|                                     |         |         |         |         |
|-------------------------------------|---------|---------|---------|---------|
| DIVIDENDS DECLARED PER COMMON SHARE | \$ 0.20 | \$ 0.20 | \$ 0.60 | \$ 0.60 |
|-------------------------------------|---------|---------|---------|---------|

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Comprehensive Income (Unaudited)****(in thousands)**

|   | <b>Three Months<br/>Ended<br/>June 30,</b> |             | <b>Nine Months<br/>Ended<br/>June 30,</b> |             |
|---|--|-------------|---|-------------|
|   | <b>2016</b>                                | <b>2015</b> | <b>2016</b>                               | <b>2015</b> |
| <b>NET EARNINGS</b>   | \$ 8,754                                   | \$ 9,102    | \$ 26,738                                 | \$ 27,073   |
| Other comprehensive income (loss):                          |  |             |   |             |
| Foreign currency translation adjustment                     | (1,563)                                    | 1,357       | (2,479)                                   | (2,146)     |
| Unrealized loss on cash flow hedge                          | (417)                                      |             | (1,111)                                   |             |
| Income taxes related to items of other comprehensive income | 228  |             | 522                                       |             |
| Other comprehensive income (loss), net of tax               | (1,752)                                    | 1,357       | (3,068)                                   | (2,146)     |
| <b>COMPREHENSIVE INCOME</b>                                 | \$ 7,002                                   | \$ 10,459   | \$ 23,670                                 | \$ 24,927   |

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Cash Flows (Unaudited)****(in thousands)**

| <b>Nine Months Ended June 30,</b>                           | <b>2016</b>      | <b>2015</b>      |
|---|------------------|------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                 |                  |                  |
| Net earnings  | \$ 26,738        | \$ 27,073        |
| Non-cash items included in net earnings:                    |                  |                  |
| Depreciation of property, plant and equipment               | 2,871            | 2,585            |
| Amortization of intangible assets                           | 1,834            | 1,309            |
| Amortization of deferred instrument costs                   | 829              | 1,088            |
| Stock-based compensation                                    | 2,654            | 2,676            |
| Deferred income taxes                                       | (753)            | (270)            |
| Losses on long-lived assets                                 | 659              | 39               |
| Change in current assets, net of acquisition                | (9,556)          | (4,399)          |
| Change in current liabilities, net of acquisition           | 868              | 796              |
| Other, net  | (140)            | 299              |
| <b>Net cash provided by operating activities</b>            | <b>26,004</b>    | <b>31,196</b>    |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                 |                  |                  |
| Purchase of property, plant and equipment                   | (2,688)          | (3,783)          |
| Purchase of equity method investment                        | (600)            |                  |
| Proceeds from sale of assets                                |                  | 1,138            |
| Acquisition of Magellan, net of cash acquired               | (62,090)         |                  |
| <b>Net cash used for investing activities</b>               | <b>(65,378)</b>  | <b>(2,645)</b>   |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                 |                  |                  |
| Dividends paid  | (25,233)         | (25,014)         |
| Proceeds from term loan, net of issuance costs              | 59,851           |                  |
| Payment on term loan  | (750)            |                  |
| Proceeds and tax benefits from exercises of stock options   | 2,033            | 654              |
| <b>Net cash provided by (used for) financing activities</b> | <b>35,901</b>    | <b>(24,360)</b>  |
| Effect of Exchange Rate Changes on Cash and Equivalents     | (697)            | (1,263)          |
| <b>Net (Decrease) Increase in Cash and Equivalents</b>      | <b>(4,170)</b>   | <b>2,928</b>     |
| Cash and Equivalents at Beginning of Period                 | 49,973           | 43,047           |
| <b>Cash and Equivalents at End of Period</b>                | <b>\$ 45,803</b> | <b>\$ 45,975</b> |

The accompanying notes are an integral part of these condensed consolidated financial statements.





Table of Contents**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets****(in thousands)**ASSETS

|   | <b>June 30,<br/>2016<br/>(Unaudited)</b> | <b>September 30,<br/>2015</b> |
|---|--|-------------------------------|
| <b>CURRENT ASSETS</b>                                   |  |                               |
| Cash and equivalents                                    | \$ 45,803                                | \$ 49,973                     |
| Accounts receivable, less allowances of \$341 and \$248 | 31,312                                   | 26,254                        |
| Inventories   | 43,409                                   | 35,817                        |
| Prepaid expenses and other current assets               | 6,396                                    | 7,378                         |
| Total current assets                                    | 126,920                                  | 119,422                       |
| <b>PROPERTY, PLANT AND EQUIPMENT, at Cost</b>           |  |                               |
| Land  | 984                                      | 986                           |
| Buildings and improvements                              | 32,042                                   | 30,056                        |
| Machinery, equipment and furniture                      | 45,893                                   | 41,541                        |
| Construction in progress                                | 1,824                                    | 1,139                         |
| Subtotal  | 80,743                                   | 73,722                        |
| Less: accumulated depreciation and amortization         | 50,670                                   | 46,230                        |
| Net property, plant and equipment                       | 30,073                                   | 27,492                        |
| <b>OTHER ASSETS</b>                                     |  |                               |
| Goodwill  | 63,698                                   | 22,349                        |
| Other intangible assets, net                            | 31,384                                   | 5,931                         |
| Restricted cash   | 1,000                                    | 1,000                         |
| Deferred instrument costs, net                          | 1,503                                    | 1,750                         |
| Deferred income taxes                                   |  | 4,954                         |
| Other assets  | 368                                      | 384                           |
| Total other assets                                      | 97,953                                   | 36,368                        |
| <b>TOTAL ASSETS</b>                                     | <b>\$ 254,946</b>                        | <b>\$ 183,282</b>             |

The accompanying notes are an integral part of these condensed consolidated financial statements.



**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets****(dollars in thousands)****LIABILITIES AND SHAREHOLDERS' EQUITY**

|  | <b>June 30,<br/>2016<br/>(Unaudited)</b> | <b>September 30,<br/>2015</b> |
|--|--|-------------------------------|
| <b>CURRENT LIABILITIES</b>   |  |                               |
| Accounts payable   | \$ 7,386                                 | \$ 6,646                      |
| Accrued employee compensation costs  | 5,425                                    | 5,132                         |
| Other accrued expenses   | 2,558                                    | 2,587                         |
| Current portion of long-term debt  | 3,375                                    |                               |
| Income taxes payable   | 1,504                                    | 886                           |
| <b>Total current liabilities</b>   | <b>20,248</b>                            | <b>15,251</b>                 |
| <b>NON-CURRENT LIABILITIES</b>   |  |                               |
| Acquisition consideration  | 2,198                                    |                               |
| Non-current compensation liabilities   | 2,252                                    | 2,158                         |
| Interest rate swap liability   | 1,111                                    |                               |
| Long-term debt   | 55,726                                   |                               |
| Deferred income taxes  | 4,558                                    |                               |
| <b>Total non-current liabilities</b>   | <b>65,845</b>                            | <b>2,158</b>                  |
| <b>COMMITMENTS AND CONTINGENCIES</b>   |  |                               |
| <b>SHAREHOLDERS' EQUITY</b>  |  |                               |
| Preferred stock, no par value; 1,000,000 shares authorized; none issued  |  |                               |
| Common shares, no par value; 71,000,000 shares authorized, 42,078,657 and 41,838,399 shares issued, respectively |  |                               |
| Additional paid-in capital   | 121,694                                  | 117,151                       |
| Retained earnings  | 52,557                                   | 51,052                        |
| Accumulated other comprehensive loss   | (5,398)                                  | (2,330)                       |
| <b>Total shareholders' equity</b>  | <b>168,853</b>                           | <b>165,873</b>                |
| <b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>  | <b>\$ 254,946</b>                        | <b>\$ 183,282</b>             |

The accompanying notes are an integral part of these condensed consolidated financial statements.



Table of Contents**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statement of Changes in Shareholders Equity (Unaudited)****(dollars and shares in thousands)**

|   | Common<br>Shares<br>Issued | Additional<br>Paid-In<br>Capital | Retained<br>Earnings | Accumulated Other<br>Comprehensive<br>Income<br>(Loss) | Total<br>Shareholders<br>Equity |
|---|----------------------------|----------------------------------|----------------------|--|---------------------------------|
| <b>Balance at September 30, 2015</b>    | 41,838                     | \$ 117,151                       | \$ 51,052            | \$ (2,330)   | \$ 165,873                      |
| Cash dividends paid                     |                            |                                  | (25,233)             |  | (25,233)                        |
| Exercise of stock options               | 125                        | 1,889                            |                      |  | 1,889                           |
| Conversion of restricted stock units    | 116                        |                                  |                      |  |                                 |
| Stock compensation expense              |                            | 2,654                            |                      |  | 2,654                           |
| Net earnings                            |                            |                                  | 26,738               |  | 26,738                          |
| Foreign currency translation adjustment |                            |                                  |                      | (2,375)  | (2,375)                         |
| Hedging activity, net of tax            |                            |                                  |                      | (693)  | (693)                           |
| <b>Balance at June 30, 2016</b>         | 42,079                     | \$ 121,694                       | \$ 52,557            | \$ (5,398)   | \$ 168,853                      |

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**Dollars in Thousands, Except Per Share Amounts**

**(Unaudited)**

**1. Basis of Presentation**

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company's financial position as of June 30, 2016, the results of its operations for the three and nine month periods ended June 30, 2016 and 2015, and its cash flows for the nine month periods ended June 30, 2016 and 2015. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's fiscal 2015 Annual Report on Form 10-K. Financial information as of September 30, 2015 has been derived from the Company's audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

The Company's Condensed Consolidated Balance Sheet as of June 30, 2016 includes the condensed balance sheet of Magellan Biosciences, Inc., and its wholly-owned subsidiary Magellan Diagnostics, Inc. (collectively, Magellan), as set forth and more fully described in Note 3. The Company's Condensed Consolidated Statements of Operations for both the three and nine months ended June 30, 2016 include Magellan's results of operations since the March 24, 2016 date of acquisition.

**2. Significant Accounting Policies**

A summary of the Company's significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company's fiscal 2015 Annual Report on Form 10-K.

**(a) Recent Accounting Pronouncements**

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers*, which supersedes and replaces nearly all currently-existing U.S. GAAP revenue recognition guidance including related disclosure requirements. This guidance, including any clarification guidance thereon, will be effective for the Company beginning October 1, 2018 (fiscal 2019). The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

In November 2015, the FASB issued ASU 2015-17, *Balance Sheet Classification of Deferred Taxes*, which simplifies the financial statement presentation of deferred income taxes by requiring that deferred income tax assets and liabilities be classified as noncurrent within a classified statement of financial position. Adoption and implementation

of the guidance is not required by the Company until issuance of fiscal 2018 first quarter financial statements. However, due to early adoption being permitted and believing the required presentation results in more useful and comparable information related to our net deferred income taxes, the Company has chosen to adopt the guidance as of December 31, 2015 and retrospectively apply the guidance to the prior period presented. This retrospective application results in \$3,431 of deferred income tax assets being reclassified from current assets to non-current assets in the September 30, 2015 balance sheet included herein. Adoption of this guidance did not have an impact on the Company's consolidated results of operations or cash flows.



## **Table of Contents**

In February 2016, the FASB issued ASU 2016-02, *Leases*, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2020, although early adoption is permitted. The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

In March 2016, the FASB issued ASU 2016-09, *Improvements to Employee Share-Based Payment Accounting*, which amends the accounting for share-based payment transactions. These changes, which are designed for simplification, involve several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2018, although early adoption is permitted. The Company has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements.

### **(b) *Reclassifications***

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders' equity.

### **3. Acquisition of Magellan**

On March 24, 2016, we acquired all of the outstanding common stock of Magellan Biosciences, Inc., and its wholly-owned subsidiary Magellan Diagnostics, Inc. (collectively, "Magellan"), for \$67,690, utilizing the proceeds from a new \$60,000 five-year term loan and cash and equivalents on hand. An amount of the acquisition consideration totaling \$2,198 remains payable to the sellers, pending the realization of tax benefits for certain net operating loss carryforwards in future tax returns. Headquartered near Boston, Massachusetts, Magellan is a leading manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Magellan is the leading provider of point-of-care lead testing systems in the U.S.

As a result of the consideration paid exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of \$42,740 was recorded in connection with this acquisition, none of which will be deductible for tax purposes. This goodwill results largely from the addition of Magellan's complementary customer base and distribution channels, industry reputation in the U.S. as a leader in lead testing, and management talent and workforce. Our Condensed Consolidated Statements of Operations for the nine months ended June 30, 2016 include \$1,173 of acquisition-related costs related to the Magellan acquisition, which are reflected as Operating Expenses.

In addition to Magellan's results of operations, which are included in our Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2016 and reported as part of the Diagnostics operating segment, the consolidated results for the three and nine months ended June 30, 2016 also include:

- (i) \$154 of cost of sales for the three and nine months, respectively, related to the roll-out of fair value inventory adjustments for sales of products that were in Magellan's inventory on the date of acquisition and, therefore, were valued at fair value, rather than manufactured cost, in the opening balance sheet; and
- (ii) \$759 of general and administrative expenses for the three and nine months, respectively, related to the depreciation of the fair value adjustment to acquired property, plant and equipment, and the amortization of specific identifiable intangible assets recorded on the opening balance sheet including customer relationships, technology, non-compete agreements, and trade names.

**Table of Contents**

The results of Magellan included in the consolidated results of the Company for the three and nine months ended June 30, 2016 are as follows, reflecting the items noted above but excluding interest expense on the debt secured by Meridian in connection with the transaction:

|              | <b>Three<br/>Months<br/>Ended<br/>June 30,<br/>2016</b> | <b>Nine<br/>Months<br/>Ended<br/>June 30,<br/>2016</b> |
|--------------|---|--|
| Net Revenues | \$ 4,752  | \$ 4,752   |
| Net Earnings | \$ 231  | \$ 231   |

The recognized preliminary amounts of identifiable assets acquired and liabilities assumed in the acquisition of Magellan are as follows:

|  | <b>PRELIMINARY</b>  |   |   |
|--|---|---|---|
|  | <b>March 24,<br/>2016<br/>(as initially<br/>reported)</b> | <b>Measurement<br/>Period<br/>Adjustments</b> | <b>March 24,<br/>2016<br/>(as adjusted)</b> |
| Fair value of assets acquired -                            |   |   |   |
| Cash and equivalents                                       | \$ 3,420  | \$ (20)                                       | \$ 3,400                                    |
| Accounts receivable  | 1,700   |   | 1,700                                       |
| Inventories  | 1,400   |   | 1,400                                       |
| Other current assets                                       | 330   | 10  | 340   |
| Property, plant and equipment                              | 2,790   | (200)   | 2,590                                       |
| Goodwill   | 42,730  | 10  | 42,740                                      |
| Other intangible assets (estimated useful life):           |   |   |   |
| Customer relationships (15 years)                          | 12,630  |   | 12,630                                      |
| Technology (10 years)                                      | 10,550  |   | 10,550                                      |
| Non-compete agreements (2 years)                           | 740   |   | 740   |
| Trade names (approximate 5 year weighted average)          | 3,690   |   | 3,690                                       |
|  | 79,980  | (200)   | 79,780                                      |
| Fair value of liabilities assumed -                        |   |   |   |
| Accounts payable and accrued expenses                      | 1,610   | (20)  | 1,590                                       |
| Deferred income tax liabilities                            | 10,570  | (70)  | 10,500                                      |
| Total consideration (including \$2,198 accrued to be paid) | \$ 67,800   | \$ (110)                                      | \$ 67,690                                   |

As indicated, the allocation of the purchase price and estimated useful lives of property, plant and equipment, and intangible assets shown remain preliminary, pending final completion of valuations. We are currently assessing the amount of tax net operating loss carryforwards available to us. Upon completion of this analysis, an amount will be

reclassified from goodwill to deferred taxes.

**Table of Contents**

The consolidated pro forma results of the combined entities of Meridian and Magellan, had the acquisition date been October 1, 2014, are as follows for the periods indicated:

|                                   | <b>Three Months Ended</b> |             | <b>Nine Months Ended</b> |             |
|-----------------------------------|---------------------------|-------------|--------------------------|-------------|
|                                   | <b>June 30,</b>           |             | <b>June 30,</b>          |             |
|                                   | <b>2016</b>               | <b>2015</b> | <b>2016</b>              | <b>2015</b> |
| Net Revenues                      | \$ 50,665                 | \$ 52,255   | \$ 156,722               | \$ 159,225  |
| Net Earnings                      | \$ 8,776                  | \$ 8,698    | \$ 26,194                | \$ 25,446   |
| Diluted Earnings Per Common Share | \$ 0.21                   | \$ 0.21     | \$ 0.62                  | \$ 0.61     |

These pro forma amounts have been calculated by including the results of Magellan, and adjusting the combined results to give effect to the following, as if the acquisition had been consummated on October 1, 2014, together with the consequential tax effects thereon:

- (i) remove the effect of transaction costs incurred by the Company;
- (ii) reflect the additional depreciation and amortization that would have been charged in connection with the preliminary fair value adjustments to inventory (\$154), property, plant and equipment (\$366) and identifiable intangible assets (\$27,610);
- (iii) reflect equity-based awards granted under the Company's 2012 Stock Incentive Plan to certain Magellan employees in accordance with executed employee agreements, and to certain Meridian employees to reward them for their efforts in connection with the transaction; and
- (iv) reflect the interest expense that would have been incurred on the Company's \$60,000 term note.

**4. Cash and Equivalents**

Cash and equivalents include the following components:

|                                  | <b>June 30, 2016</b>        |                     | <b>September 30, 2015</b>   |                     |
|----------------------------------|-----------------------------|---------------------|-----------------------------|---------------------|
|                                  | <b>Cash and Equivalents</b> | <b>Other Assets</b> | <b>Cash and Equivalents</b> | <b>Other Assets</b> |
| Overnight repurchase agreements  | \$ 7,877                    | \$                  | \$ 25,436                   | \$                  |
| Institutional money market funds | 10,010                      |                     |                             |                     |
| Cash on hand - Restricted        |                             | 1,000               |                             | 1,000               |

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 10-Q

|              |           |          |           |          |
|--------------|-----------|----------|-----------|----------|
| Unrestricted | 27,916    |          | 24,537    |          |
| Total        | \$ 45,803 | \$ 1,000 | \$ 49,973 | \$ 1,000 |

Page 10

**Table of Contents****5. Inventories**

Inventories are comprised of the following:

|                                    | <b>June<br/>30,<br/>2016</b> | <b>September 30,<br/>2015</b> |
|------------------------------------|------------------------------|-------------------------------|
| Raw materials                      | \$ 7,810                     | \$ 7,095                      |
| Work-in-process                    | 12,432                       | 10,096                        |
| Finished goods - instruments       | 2,384                        | 1,890                         |
| Finished goods - kits and reagents | 20,783                       | 16,736                        |
| <b>Total</b>                       | <b>\$ 43,409</b>             | <b>\$ 35,817</b>              |

**6. Intangible Assets**

A summary of our acquired intangible assets subject to amortization, as of June 30, 2016 and September 30, 2015, is as follows:

|  | <b>June 30, 2016</b>                |                                     | <b>September 30, 2015</b>           |                                     |
|--|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|  | <b>Gross<br/>Carrying<br/>Value</b> | <b>Accumulated<br/>Amortization</b> | <b>Gross<br/>Carrying<br/>Value</b> | <b>Accumulated<br/>Amortization</b> |
| Manufacturing technologies, core products and cell lines | \$ 21,962                           | \$ 11,270                           | \$ 11,582                           | \$ 10,906                           |
| Tradenames, licenses and patents                         | 9,852                               | 3,835                               | 6,410                               | 3,296                               |
| Customer lists and relationships, and supply agreements  | 24,283                              | 10,255                              | 12,105                              | 9,964                               |
| Non-compete agreements                                   | 740                                 | 93                                  |                                     |                                     |
|  | <b>\$ 56,837</b>                    | <b>\$ 25,453</b>                    | <b>\$ 30,097</b>                    | <b>\$ 24,166</b>                    |

The actual aggregate amortization expense for these intangible assets was \$1,072 and \$409 for the three months ended June 30, 2016 and 2015, respectively, and \$1,834 and \$1,309 for the nine months ended June 30, 2016 and 2015, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2021 is as follows: remainder of fiscal 2016 \$987, fiscal 2017 \$4,041, fiscal 2018 \$3,835, fiscal 2019 \$3,609, fiscal 2020 \$3,445, and fiscal 2021 \$2,576.

**7. Bank Credit Arrangements**

In connection with the acquisition of Magellan (see Note 3), on March 22, 2016 the Company entered into a \$60,000 five-year term loan with a commercial bank. The term loan requires quarterly principal and interest payments, with interest at a variable rate tied to LIBOR, and a balloon principal payment of \$37,500 at the end of five years. Due to the recent execution date of the term loan and interest being determined on a variable rate basis, the fair value of the term loan at June 30, 2016 approximates the current carrying value reflected in the accompanying Condensed

Consolidated Balance Sheet.

In addition, the Company continues to maintain a \$30,000 credit facility with the same commercial bank, which expires March 31, 2021. As there were no borrowings outstanding on this credit facility at June 30, 2016 or September 30, 2015, available borrowings as of both dates totaled \$30,000. The term loan and the credit facility are collateralized by the business assets of the Company's U.S. subsidiaries, and require compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the borrowing agreement. As of June 30, 2016, the Company is in compliance with all covenants.



---

**Table of Contents**

In order to limit exposure to volatility in the LIBOR interest rate, the Company and the commercial bank also entered into an interest rate swap that effectively converts the variable interest rate on the term loan to a fixed rate. With an initial notional balance of \$60,000, the interest rate swap has been established with critical terms identical to those of the term loan, including (i) notional reduction amounts and dates; (ii) LIBOR settlement rates; (iii) rate reset dates; and (iv) term/maturity. Due to this, the interest swap has been designated as an effective cash flow hedge, with changes in fair value reflected as a separate component of other comprehensive income in the accompanying Condensed Consolidated Statements of Comprehensive Income. At June 30, 2016, the fair value of the interest rate swap was a liability of \$1,111, and is reflected as a non-current liability in the accompanying Condensed Consolidated Balance Sheet. This fair value was determined by reference to a third party valuation, and is considered a Level 2 input within the fair value hierarchy of valuation techniques.

**8. Reportable Segment and Major Customers Information**

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing, and sales organization with primary emphasis in the fields of infectious disease (in vitro) and blood lead diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory, parasitic infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers and other diagnostic manufacturers.

Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment's base of manufacturing operations and research and development for infectious disease products. The Diagnostics segment includes the Company's recent acquisition of Magellan, which is located in Billerica, Massachusetts (near Boston). Its facility includes research, development, manufacturing, marketing, sales, and distribution operations. The Diagnostics segment has sales and distribution facilities for infectious disease diagnostics in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.

Amounts due from two Diagnostics distributor customers accounted for 23% and 21% of consolidated accounts receivable at June 30, 2016 and September 30, 2015, respectively. Revenues from these two distributor customers accounted for 25% and 35% of the Diagnostics segment third-party revenues during the three months ended June 30, 2016 and 2015, respectively, and 30% and 36% during the nine months ended June 30, 2016 and 2015, respectively. These distributors represented 19% and 26% of consolidated revenues for the fiscal 2016 and 2015 third quarters, respectively, and 22% and 27% for the respective year-to-date nine month periods.

Within our Life Science segment, two diagnostic manufacturing customers accounted for 23% and 16% of the segment's third-party revenues during the three months ended June 30, 2016 and 2015, respectively, and 20% and 16% during the nine months ended June 30, 2016 and 2015, respectively.

**Table of Contents**

Segment information for the interim periods is as follows:

|   | Diagnostics | Life Science | Eliminations (1) | Total      |
|---|-------------|--------------|------------------|------------|
| <b>Three Months Ended June 30, 2016</b>           |             |              |                  |            |
| Net revenues -                                    |             |              |                  |            |
| Third-party                                       | \$ 37,523   | \$ 13,142    | \$               | \$ 50,665  |
| Inter-segment                                     | 70          | 201          | (271)            |            |
| Operating income                                  | 9,886       | 3,696        | 159              | 13,741     |
| Goodwill (June 30, 2016)                          | 43,992      | 19,706       |                  | 63,698     |
| Other intangible assets, net (June 30, 2016)      | 28,848      | 2,536        |                  | 31,384     |
| Total assets (June 30, 2016)                      | 187,557     | 67,641       | (252)            | 254,946    |
| <b>Three Months Ended June 30, 2015</b>           |             |              |                  |            |
| Net revenues -                                    |             |              |                  |            |
| Third-party                                       | \$ 36,049   | \$ 12,155    | \$               | \$ 48,204  |
| Inter-segment                                     | 46          | 345          | (391)            |            |
| Operating income                                  | 11,383      | 3,060        | (45)             | 14,398     |
| Goodwill (September 30, 2015)                     | 1,250       | 21,099       |                  | 22,349     |
| Other intangible assets, net (September 30, 2015) | 2,364       | 3,567        |                  | 5,931      |
| Total assets (September 30, 2015)                 | 119,939     | 63,670       | (327)            | 183,282    |
| <b>Nine Months Ended June 30, 2016</b>            |             |              |                  |            |
| Net revenues -                                    |             |              |                  |            |
| Third-party                                       | \$ 110,178  | \$ 38,906    | \$               | \$ 149,084 |
| Inter-segment                                     | 225         | 955          | (1,180)          |            |
| Operating income                                  | 31,412      | 11,086       | (15)             | 42,483     |
| <b>Nine Months Ended June 30, 2015</b>            |             |              |                  |            |
| Net revenues -                                    |             |              |                  |            |
| Third-party                                       | \$ 111,297  | \$ 36,465    | \$               | \$ 147,762 |
| Inter-segment                                     | 235         | 867          | (1,102)          |            |
| Operating income                                  | 33,750      | 9,145        | (96)             | 42,799     |

(1) Eliminations consist of inter-segment transactions.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

---

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*Refer to Forward-Looking Statements following the Table of Contents in front of this Form 10-Q. In the discussion that follows, all dollar amounts are in thousands (both tables and text), except per share data.*

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian's financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

**RESULTS OF OPERATIONS**

**Quarterly Highlights**

As more fully detailed below, the third quarter of fiscal 2016 was highlighted by it being the first quarter to include the results of operations of Magellan Biosciences, Inc., and its wholly-owned subsidiary Magellan Diagnostics, Inc. (collectively, Magellan), which we acquired on March 24, 2016. Headquartered near Boston, Massachusetts, Magellan is a leading manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Magellan is the leading provider of point-of-care lead testing systems in the U.S. In addition, during the quarter we commercialized our *illumigene*<sup>®</sup> Mycoplasma Direct product in the U.S., representing the tenth assay for our *illumigene* molecular platform menu.

**Three Months Ended June 30, 2016**

Net earnings for the third quarter of fiscal 2016 decreased 4% to \$8,754, or \$0.21 per diluted share, from net earnings for the third quarter of fiscal 2015 of \$9,102, or \$0.22 per diluted share. Consolidated revenues increased 5% to \$50,665 for the third quarter of fiscal 2016 compared to the same period of the prior year (also up 5% on a constant-currency basis).

Revenues for the Diagnostics segment for the third quarter of fiscal 2016 increased 4% compared to the third quarter of fiscal 2015 (also up 4% on a constant-currency basis), composed of a 5% decrease in molecular products and an 8% increase in non-molecular products, reflecting \$4,800 of Magellan revenues. With 15% growth in its immunoassay components business and a 1% decline in its molecular components business, revenues of our Life Science segment increased by 8% during the third quarter of fiscal 2016 compared to the third quarter of fiscal 2015, increasing 9% on a constant-currency basis.

**Nine Months Ended June 30, 2016**

For the nine month period ended June 30, 2016, net earnings decreased 1% to \$26,738, or \$0.63 per diluted share, compared to net earnings for the comparable fiscal 2015 period of \$27,073, or \$0.64 per diluted share. Reflected within the year-to-date fiscal 2016 results are costs related to acquisition activity, including due diligence and transaction expenses related to the Magellan acquisition (\$1,233, or \$0.03 per diluted share, net of tax). Consolidated revenues increased 1% to \$149,084 for the first nine months of fiscal 2016 compared to the same period of the prior year, increasing 2% on a constant-currency basis.

During the first nine months of fiscal 2016, revenues for the Diagnostics segment decreased 1% from the comparable fiscal 2015 period (flat on a constant-currency basis), composed of a 4% decrease in molecular products and flat

non-molecular products revenue, reflecting \$4,800 of Magellan revenues. With 12% growth in its immunoassay components business and a 1% decline in its molecular components business, revenues of our Life Science segment increased by 7% during the first nine months of fiscal 2016, increasing 8% on a constant-currency basis.

**Table of Contents****REVENUE OVERVIEW**

Below are analyses of the Company's revenue, provided for each of the following:

By Reportable Segment & Geographic Region

By Product Platform/Type

**Revenue Overview By Reportable Segment & Geographic Region**

Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio and as a result of the acquisition of Magellan, manufacturing operations for products detecting elevated lead levels in blood in Billerica, Massachusetts (near Boston). These diagnostic test products are sold and distributed in the countries comprising North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA); and other countries outside of the Americas and EMEA (rest of the world, or ROW). The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia.

Revenues for the Diagnostics segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by buying patterns of major customers and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues due to these factors.

|                           | Three Months Ended June 30, |                  |           | Nine Months Ended June 30, |                   |             |
|---------------------------|-----------------------------|------------------|-----------|----------------------------|-------------------|-------------|
|                           | 2016                        | 2015             | Inc (Dec) | 2016                       | 2015              | Inc (Dec)   |
| <b>Diagnostics -</b>      |                             |                  |           |                            |                   |             |
| Americas                  | \$ 31,885                   | \$ 30,410        | 5%        | \$ 93,864                  | \$ 93,502         | %           |
| EMEA                      | 4,826                       | 4,651            | 4%        | 14,357                     | 15,184            | (5)%        |
| ROW                       | 812                         | 988              | (18)%     | 1,957                      | 2,611             | (25)%       |
| <b>Total Diagnostics</b>  | <b>37,523</b>               | <b>36,049</b>    | <b>4%</b> | <b>110,178</b>             | <b>111,297</b>    | <b>(1)%</b> |
| <b>Life Science -</b>     |                             |                  |           |                            |                   |             |
| Americas                  | 4,790                       | 5,065            | (5)%      | 16,249                     | 16,274            | %           |
| EMEA                      | 5,977                       | 4,877            | 23%       | 15,127                     | 13,637            | 11%         |
| ROW                       | 2,375                       | 2,213            | 7%        | 7,530                      | 6,554             | 15%         |
| <b>Total Life Science</b> | <b>13,142</b>               | <b>12,155</b>    | <b>8%</b> | <b>38,906</b>              | <b>36,465</b>     | <b>7%</b>   |
| <b>Consolidated</b>       | <b>\$ 50,665</b>            | <b>\$ 48,204</b> | <b>5%</b> | <b>\$ 149,084</b>          | <b>\$ 147,762</b> | <b>1%</b>   |

% of total revenues -

|              |             |             |             |             |
|--------------|-------------|-------------|-------------|-------------|
| Diagnostics  | 74%         | 75%         | 74%         | 75%         |
| Life Science | 26%         | 25%         | 26%         | 25%         |
| <b>Total</b> | <b>100%</b> | <b>100%</b> | <b>100%</b> | <b>100%</b> |
| Ex-Americas  | 28%         | 26%         | 26%         | 26%         |

**Table of Contents****Revenue Overview By Product Platform/Type**

The revenues generated by each of our reportable segments result primarily from the sale of the following segment-specific categories of products:

**Diagnostics**

- 1) Molecular tests that operate on our *illumigene* platform
- 2) Non-molecular tests on multiple technology platforms

**Life Science**

- 1) Molecular components
- 2) Immunoassay components

Revenues for each product platform/type, as well as its relative percentage of segment revenue, are shown below.

|                                     | Three Months Ended June 30, |                  |           | Nine Months Ended June 30, |                   |             |
|-------------------------------------|-----------------------------|------------------|-----------|----------------------------|-------------------|-------------|
|                                     | 2016                        | 2015             | Inc (Dec) | 2016                       | 2015              | Inc (Dec)   |
| <b>Diagnostics -</b>                |                             |                  |           |                            |                   |             |
| Molecular                           | \$ 10,063                   | \$ 10,550        | (5)%      | \$ 29,564                  | \$ 30,650         | (4)%        |
| Non-molecular                       | 27,460                      | 25,499           | 8%        | 80,614                     | 80,647            | %           |
| <b>Total Diagnostics</b>            | <b>\$ 37,523</b>            | <b>\$ 36,049</b> | <b>4%</b> | <b>\$ 110,178</b>          | <b>\$ 111,297</b> | <b>(1)%</b> |
| <b>Life Science -</b>               |                             |                  |           |                            |                   |             |
| Molecular components                | \$ 5,037                    | \$ 5,104         | (1)%      | \$ 14,902                  | \$ 15,009         | (1)%        |
| Immunoassay components              | 8,105                       | 7,051            | 15%       | 24,004                     | 21,456            | 12%         |
| <b>Total Life Science</b>           | <b>\$ 13,142</b>            | <b>\$ 12,155</b> | <b>8%</b> | <b>\$ 38,906</b>           | <b>\$ 36,465</b>  | <b>7%</b>   |
| <b>% of Diagnostics revenues -</b>  |                             |                  |           |                            |                   |             |
| Molecular                           | 27%                         | 29%              |           | 27%                        | 28%               |             |
| Non-molecular                       | 73%                         | 71%              |           | 73%                        | 72%               |             |
| <b>Total Diagnostics</b>            | <b>100%</b>                 | <b>100%</b>      |           | <b>100%</b>                | <b>100%</b>       |             |
| <b>% of Life Science revenues -</b> |                             |                  |           |                            |                   |             |
| Molecular components                | 38%                         | 42%              |           | 38%                        | 41%               |             |
| Immunoassay components              | 62%                         | 58%              |           | 62%                        | 59%               |             |

|                    |      |      |      |      |
|--------------------|------|------|------|------|
| Total Life Science | 100% | 100% | 100% | 100% |
|--------------------|------|------|------|------|

Following is a discussion of the revenues generated by each of these product platforms/types:

**Diagnostics Products**

Molecular Products

Revenues for our *illumigene* molecular platform of products decreased 5% to \$10,000 for the fiscal 2016 third quarter (also 5% in constant-currency), and decreased 4% to \$29,600 for the nine month year-to-date period (3% in constant-currency). These decreases reflect the ongoing intense competition within the molecular-based testing market.

We have nearly 1,600 customer account placements, adding 25 customers and 35 assays since our last report. Of these account placements, approximately 1,300 accounts have completed evaluations and validations and are regularly purchasing product, with the balance of our account placements being in some stage of product evaluation and/or validation. Of our account placements, we have over 400 accounts that are regularly purchasing, evaluating and/or validating two or more assays.



**Table of Contents**

We continue to invest in new product development for our molecular testing platform, and this platform now has the following commercialized tests:

1. *illumigene*<sup>®</sup> *C. difficile* commercialized in August 2010
  2. *illumigene*<sup>®</sup> Group B *Streptococcus* (Group B Strep or GBS) commercialized in December 2011
  3. *illumigene*<sup>®</sup> Group A *Streptococcus* (Group A Strep) commercialized in September 2012
  4. *illumigene*<sup>®</sup> Mycoplasma (*M. pneumoniae*; walking pneumonia) commercialized in June 2013
  5. *illumigene*<sup>®</sup> *Bordetella pertussis* (whooping cough) commercialized in March 2014
  6. *illumigene*<sup>®</sup> *Chlamydia trachomatis* commercialized outside of U.S. in February 2015
  7. *illumigene*<sup>®</sup> *Neisseria gonorrhoea* commercialized outside of U.S. in February 2015
  8. *illumigene*<sup>®</sup> HSV 1&2 (Herpes Simplex Virus Type 1 & Type 2) commercialized in July 2015
  9. *illumigene*<sup>®</sup> Malaria commercialized outside of U.S. in February 2016
  10. *illumigene*<sup>®</sup> Mycoplasma Direct (*M. pneumoniae*; walking pneumonia) commercialized in June 2016
- We believe that the diagnostic testing market is continuing to selectively move away from culture and immunoassay testing to molecular testing for diseases where there is a favorable cost/benefit position for the total cost of health care. While this market is competitive, with molecular companies such as Cepheid and Becton Dickinson, and others such as Quidel, Great Basin, Nanosphere, and Alere, we believe we are well-positioned to capitalize on the migration to molecular testing. Our simple, easy-to-use, *illumigene* platform, with its expanding menu, requires no expensive equipment purchase and little to no maintenance cost. We believe these features, along with its small footprint and the performance of the *illumigene* assays, make *illumigene* an attractive molecular platform to any size hospital or physician office laboratory that runs moderately-complex tests.

**Non-molecular Products**

Revenues from our Diagnostics segment's non-molecular products increased 8% in the third quarter of fiscal 2016 and were flat on a nine month year-to-date basis. These results reflect the addition of Magellan's revenue, increased revenues in our *H. pylori* immunoassay products and an overall decrease in revenues of our other immunoassay product lines.

Since the March 24, 2016 acquisition, revenues from Magellan's sales of products to test for elevated levels of lead in blood have totaled \$4,800—all of which, as previously noted, are reflected within Meridian's results for the three and nine months ended June 30, 2016. This level of revenues reflects a 17% increase over the three-month period ended June 30, 2015, which was prior to Meridian ownership.

During the fiscal 2016 third quarter, revenues from our *H. pylori* products increased 1% (also 1% in constant-currency) to \$8,100. These revenues grew 9% to \$25,100 during the first nine months of fiscal 2016 (10% in constant-currency). These increases continue to reflect the benefits of our partnerships with managed care companies in promoting (i) the health and economic benefits of a test and treat strategy; (ii) changes in policies that discourage the use of traditional serology methods and promote the utilization of active infection testing methods; and (iii) physician behavior movement away from serology-based testing and toward direct antigen testing. A significant amount of the *H. pylori* product revenues are sales to reference labs, whose buying patterns may not be consistent from period to period. In addition to our managed care strategy, we have also employed bulk-buy sales promotions into selected distribution and laboratory channels as a defensive strategy against potential new competitive product introductions expected later in the year.

The patents for our *H. pylori* products are owned by us and expired in May 2016 in the U.S. and will expire in 2017 in countries outside the U.S. We expect competition with respect to our *H. pylori* products to increase in 2016 and 2017 as we currently market the only FDA-cleared test to detect *H. pylori* antigen in stool samples. Such competition may have an adverse impact on our selling prices for these products, or our ability to retain business at prices acceptable to us, and consequently, adversely affect our future results of operations and liquidity, including revenues and gross profit. In order to mitigate any loss in revenues, among other things, we are researching and experimenting with new products and attempting to secure significant customers under long-term contracts. We are unable to provide any assurances that we will be successful with any mitigation strategy or that any mitigation strategy will prevent an adverse effect on our future results of operations and liquidity, including revenues and gross profit.

**Table of Contents**

During the fiscal 2016 third quarter, revenues from our other immunoassay products (including *C. difficile*, foodborne and respiratory) decreased 18% (also 18% in constant-currency) to \$14,400. These revenues decreased 13% to \$49,700 during the first nine months of fiscal 2016 (12% in constant-currency). These decreases result primarily from the effects of continued increased competition, distributor order patterns and the timing of our promotional stock-and-block programs in previous periods.

**Life Science Products**

During the third quarter of fiscal 2016, revenues from our Life Science segment increased 8%, with revenues from molecular component sales decreasing 1% from the comparable fiscal 2015 quarter and revenues from immunoassay component sales increasing 15%. For the first nine months of fiscal 2016, revenues from our Life Science segment increased 7%, with revenues from molecular component sales decreasing 1% from the year-to-date fiscal 2015 period and revenues from immunoassay component sales increasing 12%. Our molecular component business growth was negatively impacted by the movement in currency exchange rates since the fiscal 2015 periods, with revenues increasing 2% and 3% on a constant-currency basis over the third quarter and first nine months of fiscal 2015, respectively. The weaker growth compared to the last several years is primarily due to several large customers delaying orders in connection with their new product launches and recent customer merger activity. Our Life Science segment continued to benefit from increased sales into China, with such sales totaling approximately \$500 and \$2,000 during the fiscal 2016 third quarter and year-to-date periods, respectively, primarily in the immunoassay components business; representing an approximate 25% increase over the fiscal 2015 year-to-date period.

***Significant Customers***

Revenue concentrations related to certain customers within our Diagnostics and Life Science segments are set forth in Note 8 of the accompanying Condensed Consolidated Financial Statements.

***Medical Device Tax***

On January 1, 2013, the medical device tax established as part of the U.S. health care reform legislation became effective, and as a result, the Company made its first required tax deposit near the end of January 2013. During the first nine months of fiscal 2016 and fiscal 2015, the Company recorded approximately \$500 and \$1,500, respectively, of medical device tax expense (\$0 and \$500 in the third quarters of fiscal 2016 and 2015, respectively), which is reflected as a component of cost of sales in the accompanying Condensed Consolidated Statements of Operations. During December 2015, the Consolidations Appropriations Act of 2016 imposed a two-year moratorium on this excise tax effective January 1, 2016. During calendar years 2016 and 2017, this moratorium would result in approximately \$2,000 of savings each year. We are unable to predict any future legislative changes or developments related to this moratorium or excise tax.

**Gross Profit**

|                     | Three Months Ended June 30, |           |           | Nine Months Ended June 30, |           |           |
|---------------------|-----------------------------|-----------|-----------|----------------------------|-----------|-----------|
|                     | 2016                        | 2015      | Change    | 2016                       | 2015      | Change    |
| Gross Profit        | \$ 32,909                   | \$ 30,331 | 8%        | \$ 98,064                  | \$ 92,089 | 6%        |
| Gross Profit Margin | 65%                         | 63%       | +2 points | 66%                        | 62%       | +4 points |

The overall gross profit increases experienced in fiscal 2016 primarily result from the combined effects of (i) mix of products sold, particularly the higher revenue contribution from *H. pylori* products; (ii) realization of manufacturing

facility efficiencies for our *illumigene* products as a result of bringing in-house certain reagent dispensing operations that were previously outsourced; (iii) manufacturing efficiencies in our Life Science segment; and (iv) favorable effects of currency rates related to products where the purchase cost is denominated in Euros but the customer sales are billed in U.S. dollars. Product revenue mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

**Table of Contents****Operating Expenses****Three Months Ended June 30, 2016**

|   | <b>Research<br/>&amp;<br/>Development</b> | <b>Selling<br/>&amp;<br/>Marketing</b> | <b>General &amp;<br/>Administrative</b> | <b>Acquisition-<br/>Related Costs</b> | <b>Total Operating<br/>Expenses</b> |
|---|---|--|---|---------------------------------------|-------------------------------------|
| <b>2015 Expenses</b>                      | \$ 3,214                                  | \$ 6,184                               | \$ 6,535                                | \$                                    | \$ 15,933                           |
| % of Revenues                             | 7%  | 13%                                    | 14%                                     | %                                     | 33%                                 |
| <b>Fiscal 2016 Increases (Decreases):</b> |   |  |   |                                       |                                     |
| Diagnostics                               | 389                                       | 1,702                                  | 1,285                                   |                                       | 3,376                               |
| Life Science                              | (57)                                      | 199                                    | (283)                                   |                                       | (141)                               |
| <b>2016 Expenses</b>                      | \$ 3,546                                  | \$ 8,085                               | \$ 7,537                                | \$                                    | \$ 19,168                           |
| % of Revenues                             | 7%  | 16%                                    | 15%                                     | %                                     | 38%                                 |
| % Increase (Decrease)                     | 10%                                       | 31%                                    | 15%                                     | %                                     | 20%                                 |

**Nine Months Ended June 30, 2016**

|   | <b>Research<br/>&amp;<br/>Development</b> | <b>Selling<br/>&amp;<br/>Marketing</b> | <b>General &amp;<br/>Administrative</b> | <b>Acquisition-<br/>Related Costs</b> | <b>Total Operating<br/>Expenses</b> |
|---|---|--|---|---------------------------------------|-------------------------------------|
| <b>2015 Expenses</b>                      | \$ 9,685                                  | \$ 18,745                              | \$ 20,860                               | \$                                    | \$ 49,290                           |
| % of Revenues                             | 7%  | 13%                                    | 14%                                     | %                                     | 33%                                 |
| <b>Fiscal 2016 Increases (Decreases):</b> |   |  |   |                                       |                                     |
| Diagnostics                               | 667                                       | 2,033                                  | 1,476                                   | 1,481                                 | 5,657                               |
| Life Science                              | (296)                                     | 960                                    | (30)                                    |                                       | 634                                 |
| <b>2016 Expenses</b>                      | \$ 10,056                                 | \$ 21,738                              | \$ 22,306                               | \$ 1,481                              | \$ 55,581                           |
| % of Revenues                             | 7%  | 15%                                    | 15%                                     | 1%                                    | 37%                                 |
| % Increase                                | 4%  | 16%                                    | 7%                                      | NMF                                   | 13%                                 |

Total operating expenses increased during both the third quarter of fiscal 2016 and the first nine months of fiscal 2016 compared to the corresponding fiscal 2015 periods. These levels of operating expenses result primarily from the combined effects of the following:

**Diagnostics****Quarterly**

Addition of Magellan's operating expenses, which represent approximately 75% of the total Diagnostics operating expense increase; and

Increased investment in Sales & Marketing activities, including the addition of new sales territories.

Year-to-Date

Addition of Magellan's operating expenses, which represent approximately 45% of the total Diagnostics operating expense increase;

Increased investment in Sales & Marketing activities, including the addition of new sales territories; and

Costs in connection with acquisition activities, most notably related to the acquisition of Magellan.

## **Table of Contents**

### **Life Science**

#### **Quarterly & Year-to-Date**

Increased investment in Sales & Marketing activities, including increased personnel, travel and marketing spending

#### **Operating Income**

Operating income decreased 5% to \$13,741 for the third quarter of fiscal 2016, and decreased 1% to \$42,483 for the first nine months of fiscal 2016, as a result of the factors discussed above.

#### **Income Taxes**

The effective rate for income taxes was 35% and 36% for the third quarters of fiscal 2016 and 2015, respectively, and 36% and 35%, respectively, for the nine-month year-to-date periods ended June 30, 2016 and 2015, respectively. The year-to-date increase primarily results from the non-deductibility of certain expenses incurred in connection with the Company's acquisition activities. For the fiscal year ending September 30, 2016, we expect the effective tax rate to approximate 35%-36%.

### **Liquidity and Capital Resources**

#### ***Comparative Cash Flow Analysis***

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities.

We have an investment policy that guides the holdings of our investment portfolio, which presently consists of overnight repurchase agreements, bank savings accounts and institutional money market mutual funds (beginning in April). Our objectives are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy's investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

On June 23, 2016, the United Kingdom voted to leave the European Union (commonly referred to as "Brexit") and while the impact of Brexit remains very uncertain, the resulting immediate changes in foreign currency exchange rates has limited overall impact due to natural hedging. However, the predicted deterioration in the United Kingdom and European economic outlook may have an adverse effect on revenue growth, but the extent of such effect cannot yet be quantified. In the longer term, it is highly likely we will be directly impacted in a number of key areas including the hiring and retention of qualified staff, regulatory affairs, manufacturing and logistics. We are closely monitoring the Brexit developments in order to determine, quantify and proactively address changes as they become clear. Despite the Brexit developments, overall we do not expect economic conditions to have a significant impact on our liquidity needs, financial condition or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our \$30,000 bank credit facility. Our liquidity needs may change if overall economic conditions change and/or liquidity and credit within the financial

markets tightens for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable or impact credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities totaled \$26,004 for the first nine months of fiscal 2016, a 17% decrease from the \$31,196 provided during the first nine months of fiscal 2015. While reflecting the effects of the timing of payments from customers and to suppliers and taxing authorities, this decrease also results in large part from the increase in inventory levels. The levels of inventory in our Life Science segment have been increased in anticipation of demand related to various initiatives, most notably further expansion into the Asian market. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months.



## **Table of Contents**

As described in Notes 3 and 7 of the accompanying Condensed Consolidated Financial Statements, on March 24, 2016, the Company acquired all of the outstanding common stock of Magellan for \$67,690, utilizing the proceeds from a new \$60,000 five-year term loan and cash and equivalents on hand. An amount of the acquisition consideration totaling \$2,198 remains payable to the sellers, pending the realization of tax benefits for certain net operating loss carryforwards in future tax returns.

### ***Capital Resources***

We have a \$30,000 credit facility with a commercial bank that expires on March 31, 2021. As of July 31, 2016, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first nine months of fiscal 2016 or during the full year of fiscal 2015.

Our capital expenditures are estimated to range between approximately \$3,000 to \$4,000 for fiscal 2016, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the \$30,000 credit facility discussed above.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes in the Company's exposure to market risk since September 30, 2015.

### **ITEM 4. CONTROLS AND PROCEDURES**

As of June 30, 2016, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of June 30, 2016. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the third fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to June 30, 2016. We routinely refine our internal controls over financial reporting in the normal course of business as new business activities arise or risks change. These refinements are made under a program of continuous improvement.

**Table of Contents**

**PART II. OTHER INFORMATION**

**ITEM 1A. RISK FACTORS**

There have been no material changes from risk factors as previously disclosed in the Registrant's Form 10-K in response to Item 1A to Part I of Form 10-K.

**ITEM 5. OTHER INFORMATION**

Our Board of Directors authorized us to enter into change in control severance agreements with our executive officers (other than our Chief Executive Officer who has change of control provisions in his Employment Agreement), which were executed effective August 4, 2016. Each agreement has an initial term ending December 31, 2016, and each year will automatically renew for an additional one year term, provided however, that if a change in control occurs the term will expire no earlier than 24 calendar months after the calendar month in which such change in control occurs. The change in control severance agreements replace the Company's change in control policy which was adopted by the Board in March 2011. This agreement is the result of Management's and the Board's periodic review and updates of certain policies and practices. A change of control is generally defined in each agreement as any of the following: (i) a person is or becomes a beneficial owner of more than 50% of our voting securities; (ii) the composition of a majority of our Board changes; (iii) we consummate a merger or similar transaction; (iv) the sale of all or substantially all of our assets; or (v) the employment of a Chief Executive Officer other than the Company's current CEO as of the date of the agreement. Each agreement provides, among other things, that if a change in control occurs during the term of the agreement, and the executive's employment is terminated either by us or by the executive, other than: (a) by us for cause; (b) by reason of death or disability; or (c) by the executive without good reason, such executive will receive a severance payment equal to: (A) a multiple of such executive's annual base salary; (B) a multiple of executive's target bonus amounts; and (C) earned but unused vacation time. In addition, each change in control agreement provides that in the event that the severance and other benefits provided for in the agreement or otherwise payable to the executive would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, the benefits under the agreement will be either delivered in full, or delivered to a lesser extent which would result in no portion of the benefits being subject to such excise tax, whichever is more beneficial to the executive.

**ITEM 6. EXHIBITS**

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.

- 10.1 Form of Meridian Bioscience, Inc. Change in Control Agreement dated August 4, 2016 (filed herewith)
- 10.2 Letter Agreement dated July 26, 2016 between the Company and Richard L. Eberly (filed herewith)
- 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
- 31.2 Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
- 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101 The following financial information from Meridian Bioscience Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed with the SEC on August 9, 2016, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2016 and

2015; (ii) Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended June 30, 2016 and 2015; (iii) Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 2016 and 2015; (iv) Condensed Consolidated Balance Sheets as of June 30, 2016 and September 30, 2015; (v) Condensed Consolidated Statement of Shareholders' Equity for the nine months ended June 30, 2016; and (vi) the Notes to Condensed Consolidated Financial Statements

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MERIDIAN BIOSCIENCE, INC.**

Date: August 9, 2016

By: /s/ Melissa A. Lueke  
Melissa A. Lueke  
Executive Vice President and Chief Financial Officer  
  
(Principal Financial and Accounting Officer)

Page 23